Theracryf Plc

Research Theracryf Plc (TCF) on Bullrun: market cap GBX 505.01M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerTCF
• ExchangeLSE
• CountryUnited Kingdom
• SectorHealthcare
• IndustryBiotechnology
• CurrencyGBX
• Market capGBX 505.01M
• Financial periodFY2025
• Revenue growth-100.0%
• Net income-GBP 1.94M
• Free cash flow-GBP 2.37M

Valuation Snapshot

latest market cap is GBX 505.01M.

About Theracryf Plc

Theracryf Plc, a clinical stage therapeutics company, engages in the development of therapeutics for oncology and behavioural brain disorders. The company develops orexin-1 antagonist for the treatment of binge eating disorder and anxiety; and atypical dopamine transporter inhibitor (DAT) to treat fatigue and narcolepsy. It also develops SFX-01 for the treatment of brain cancer glioblastoma and neurodevelopmental disorders.

Frequently asked questions

What is Theracryf Plc's market cap?

Theracryf Plc's market capitalization is GBX 505.01M.

What does Theracryf Plc do?

Theracryf Plc, a clinical stage therapeutics company, engages in the development of therapeutics for oncology and behavioural brain disorders. The company develops orexin-1 antagonist for the treatment of binge eating disorder and anxiety;